Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRT6019 safety and PK in healthy males
NCT07317063Phase 1Completed
- Sponsor
- Grünenthal GmbH
- Start
- Nov 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tegacorat in Duchenne muscular dystrophy (DMD), sponsored by Grünenthal GmbH. Primary endpoints: Adverse Events at 7 weeks, Serious Adverse Events at 7 weeks and 2 more. Started Nov 2025; status: completed.
02
Drugs
tegacorat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07317063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07317063.